Trial Outcomes & Findings for A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee (NCT NCT01689337)
NCT ID: NCT01689337
Last Updated: 2017-01-13
Results Overview
The dGEMRIC is an imaging technique that estimates the proteoglycan (and glycosaminoglycan) content of joint cartilage using spin-lattice relaxation time T1 after penetration of gadolinium contrast agent. Composition of the refilled cartilage was to be reported.
TERMINATED
PHASE2
1 participants
6 months post-MFx surgery
2017-01-13
Participant Flow
Sprifermin (AS902330) 30 microgram (mcg) and placebo arms were planned, but did not enroll participants due to early study discontinuation.
Participant milestones
| Measure |
Sprifermin (AS902330), 100 mcg
Sprifermin (AS902330) was administered at a dose of 100 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after microfracture (MFx) surgery.
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
Sprifermin (AS902330), 100 mcg
Sprifermin (AS902330) was administered at a dose of 100 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after microfracture (MFx) surgery.
|
|---|---|
|
Overall Study
Study Discontinuation
|
1
|
Baseline Characteristics
A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee
Baseline characteristics by cohort
| Measure |
Sprifermin (AS902330), 100 mcg
n=1 Participants
Sprifermin (AS902330) was administered at a dose of 100 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after microfracture (MFx) surgery.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
|
Gender
Female
|
0 Participants
n=99 Participants
|
|
Gender
Male
|
1 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: 6 months post-MFx surgeryPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The dGEMRIC is an imaging technique that estimates the proteoglycan (and glycosaminoglycan) content of joint cartilage using spin-lattice relaxation time T1 after penetration of gadolinium contrast agent. Composition of the refilled cartilage was to be reported.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 years beyond 6 months post-MFx surgeryPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The dGEMRIC is an imaging technique that estimates the proteoglycan (and glycosaminoglycan) content of joint cartilage using spin-lattice relaxation time T1 after penetration of gadolinium contrast agent. Composition of the refilled cartilage was to be reported.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The KOOS Version LK1.0 is a knee-specific self-administered questionnaire used to assess pain, function, quality of life, and ADL. It consists of 42 items grouped into 5 subscales: pain, other symptoms (including swelling, restricted range of motion, and mechanical symptoms), function in ADL, function in sport and recreation (FSR), and impact on quality of life (QOL) (knee-related QOL, including awareness of the knee condition and changes in lifestyle). The subscales are scored separately; each yields a score between 0 and 100, with 0 representing extreme knee problems and 100 representing absence of problems. Total KOOS score is the average of all 5 subscale scores; ranging from 0 to 100; where 0 represents extreme knee problems and 100 represents absence of knee problems. Change from baseline in pain and ADL sub-scores was to be calculated by the respective scores at the specific time point minus the scores at baseline.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The KOOS Version LK1.0 is a knee-specific self-administered questionnaire used to assess pain, function, quality of life, and ADL. It consists of 42 items grouped into 5 subscales: pain, other symptoms (including swelling, restricted range of motion, and mechanical symptoms), function in ADL, FSR, and impact on QOL (knee-related QOL, including awareness of the knee condition and changes in lifestyle). The subscales are scored separately; each yields a score between 0 and 100, with 0 representing extreme knee problems and 100 representing absence of problems. Total KOOS score is the average of all 5 subscale scores; ranging from 0 to 100; where 0 represents extreme knee problems and 100 represents absence of knee problems. Change from baseline in total KOOS score; other symptoms, knee-related QOL, and FSR sub-scores; and total KOOS minus FSR sub-score was to be calculated by the respective scores at the specific time point minus the scores at baseline.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
Knee pain was to be rated by the participant using an 11-point NRS of pain intensity. The NRS is scaled from 0 (no pain) to 10 (worst possible pain). Change from baseline in NRS score was to be calculated by the score at the specific time point minus the score at baseline.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The LEAS is an 18-level single-question self-administered scale that has been validated as a clinical outcome measure for the assessment of participants' actual activity levels. The LEAS is scaled from 1 to 18, with 18 indicating levels of highest activity. Change from baseline in LEAS score was to be calculated by the score at the specific time point minus the score at baseline.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The Lysholm knee scale is a physician-reported outcome measure to assess knee function after ligament injury. It is scaled from 0 to 100 with higher scores representing better function. Change from baseline in Lysholm knee scale score was to be calculated by the score at the specific time point minus the score at baseline.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The transverse relaxation time T2 mapping is an MRI technique that is able to evaluate collagen organization and orientation within cartilage. Composition of the refilled cartilage was to be reported.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
Volume of the refilled cartilage was to be measured by MRI.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 6 months up to 5 yearsPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
The MOCART score is used to describe the constitution of the cartilage repair tissue and the surrounding structures.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Every 3 months up to 5 years beyond Month 6 post-MFx surgeryPopulation: Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
Six (6)-minute walk test is used to measure gait function and for pre- and post-operative evaluation in cartilage injury repair. Maximum comfortable distance (in meters) that a participant can walk in 6 minutes was to be reported.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline up to Month 60Population: The safety analysis set included all participants who received at least 1 dose of trial drug.
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE is an AE that results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
Outcome measures
| Measure |
Sprifermin (AS902330), 100 mcg
n=1 Participants
Sprifermin (AS902330) was administered at a dose of 100 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
|
|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Adverse Events
|
1 participants
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Serious Adverse Events
|
0 participants
|
Adverse Events
Sprifermin (AS902330), 100 mcg
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Sprifermin (AS902330), 100 mcg
n=1 participants at risk
Sprifermin (AS902330) was administered at a dose of 100 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after microfracture (MFx) surgery.
|
|---|---|
|
Nervous system disorders
Syncope
|
100.0%
1/1 • Up to 6 months
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
100.0%
1/1 • Up to 6 months
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug.
|
|
Psychiatric disorders
Panic attack
|
100.0%
1/1 • Up to 6 months
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug.
|
|
General disorders
Pyrexia
|
100.0%
1/1 • Up to 6 months
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug.
|
|
Infections and infestations
Streptococcal pharyngitis
|
100.0%
1/1 • Up to 6 months
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug.
|
|
Musculoskeletal and connective tissue disorders
Knee swelling
|
100.0%
1/1 • Up to 6 months
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug.
|
Additional Information
Merck KGaA Communication Center
Merck Serono, a division of Merck KGaA
Results disclosure agreements
- Principal investigator is a sponsor employee The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can with reasonable grounds require changes to the communication which do not change the scientific statement or neutrality of the communication.
- Publication restrictions are in place
Restriction type: OTHER